Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Portfolio Pulse from
The article compares Amgen and Merck, two Dow Jones Industrial Average healthcare stocks, analyzing their valuation, growth prospects, and current market performance. While Merck appears cheaper based on P/E ratio, Amgen shows stronger revenue growth and promising future developments.
March 28, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck experiences slower growth, disappointing Gardasil vaccine sales, and uncertainty around Keytruda patent expiration.
Challenges in vaccine sales and potential patent loss for key drug suggest potential short-term stock price pressure
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Amgen shows robust performance with 19% revenue growth, best-in-class blockbusters, and promising MariTide obesity drug in phase 3 trials.
Strong revenue growth, promising drug pipeline, and market outperformance suggest positive short-term stock movement
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100